Search

everythinglearnresearchcommunity

for

Search:↓

A user shared their 2+ years progress on Oral Dutasteride and Sublingual Minoxidil for hair loss. Another user asked about the form of Minoxidil used sublingually.

Dutasteride takes 1-3 months to affect scalp DHT levels, not just a week. The prostate absorbs Dutasteride faster than the scalp due to different vascular networks and enzyme densities.

Delayed release oral minoxidil is seen as a promising advancement for hair loss treatment, offering safer, higher doses and more consistent hair follicle stimulation compared to current options. However, it is not expected to replace finasteride or dutasteride, as it does not prevent androgenetic alopecia.

Scalp tension may contribute to hair loss by increasing DHT levels, with potential solutions like scalp massages and Botox. Concerns about finasteride's side effects were discussed, and some users shared personal experiences with alternative treatments like scalp massaging and Botox.

A user experienced heart problems after taking 1mg finasteride and 2.5mg oral minoxidil and is considering quitting minoxidil. Others discussed their experiences with heart issues and minoxidil, with some suggesting topical minoxidil as a safer alternative.

12 companies having drugs or therapies in clinical trials during 2023, with various molecules and phases of trial; the probability that some may fail; and progress being made in the field.

Clascoterone is considered overhyped and not as effective as finasteride or dutasteride, but it may be useful as a supportive treatment in combination with other therapies. Users express skepticism about its effectiveness compared to clinical trials, with some suggesting it could be beneficial for those who cannot tolerate other treatments.

Clascoterone has shown promising results in increasing hair density without systemic side effects, potentially offering benefits similar to finasteride. There is skepticism due to the lack of published photos despite the market interest.

Dutasteride is more effective than Finasteride for hair loss, with similar safety profiles. Individual responses vary, and factors like Minoxidil use and age differences may influence results.

The FDA warned that topical finasteride can cause serious side effects like sexual dysfunction and brain fog, similar to oral finasteride. Compounded topical formulations pose additional risks due to lack of regulation.

Kintor's 1% Pyrilutamide will be released in October/November. The user cannot tolerate finasteride.

Topical finasteride concentrations are likely much higher than necessary for effective follicular DHT suppression, with current standards being 100-1000 times above the theoretical minimum. Lower concentrations (0.001-0.0025%) might still work locally while minimizing systemic exposure.

Clascoterone is a topical treatment for androgenetic alopecia, showing modest to moderate hair regrowth, and may be available by 2027-2028. It is considered safer than finasteride, with discussions on its effectiveness compared to RU58841 and pyrilutamide.

Switching from oral to topical dutasteride can cause shedding due to changes in DHT levels, and it's recommended to overlap both treatments to minimize this effect. Topical dutasteride may cause scalp irritation, and the user is considering dutasteride mesotherapy as an alternative.

Clascoterone (Breezula) shows a potential 500% increase in hair growth, possibly outperforming minoxidil and finasteride. It is in advanced trials, with hopes for FDA approval, but cost and side effects are concerns.

The conversation discusses skepticism about group buys for hair loss treatments, highlighting issues with unverified chemicals and the risks involved. It suggests stabilizing with dutasteride and minoxidil, and considering a hair transplant instead of experimenting with untested products.

Topical dutasteride is considered for hair loss, but concerns about systemic absorption and side effects like reduced libido are common. Users have mixed results, with some preferring oral finasteride or dutasteride despite side effects, while others find topical treatments beneficial but challenging.

A 23-year-old shares progress in hair quality after 4 months using dutasteride, topical minoxidil, and other treatments, noting improved crown thickness but persistent temple thinning. They switched from finasteride to dutasteride due to side effects and started testosterone replacement therapy, which they believe helps mitigate side effects.

Veradermics' new hair loss treatment, VDPHL01, is likely a modified release oral minoxidil, which has received $75 million in funding for clinical trials. Despite skepticism about investing in a known treatment, some believe it could offer improved efficacy and reduced side effects.

A user experienced increased shedding after adding KX-826 to their long-term finasteride and minoxidil regimen. Another user reported mild side effects from KX-826, such as stomach and testicle pain.

The conversation is about purchasing KX-826 (Pyrilutamide) on Amazon, now called Koshine. A user mentioned their order is expected to arrive between August 22 and September 13.

The user switched from topical minoxidil/dutasteride to oral dutasteride, resulting in hair loss. They resumed topical treatment without regrowth and are considering switching to finasteride due to poor results with oral dutasteride.

SCUBE3, a protein linked to hair growth in moles, was discovered over 25 years ago and is being developed by Amplifica for potential hair loss treatment. Concerns exist about SCUBE3's association with cancer, as it is a protein that promotes cell growth, which could potentially trigger cancer development if used for hair growth therapy.

The user's consideration of taking finasteride as a short-term treatment, while awaiting advances in medical technology such as Pyrilutamide and GT20029; other users' experiences with Finasteride, including potential side effects.

Pyrilutamide, a potential hair loss treatment that is currently in development and may be available soon; an androgen receptor degrader which is also being developed as a potential treatment for hair loss; and the comparison between Pyrilutamide, finasteride, minoxidil, and RU58841.

Finasteride prescriptions in France now require an annual certificate acknowledging psychiatric and sexual risks, as the European Medicines Agency recognizes these risks. The conversation discusses the potential mental health effects of Finasteride, with some users reporting side effects and others questioning the statistical significance of these findings.

PP405 shows potential for hair growth by increasing terminal hair and converting vellus hairs, but results are modest and more waiting is needed. It complements existing treatments like minoxidil and finasteride, but won't replace them.

Finasteride prices in Canada vary, with Costco offering lower prices compared to smaller pharmacies, and no membership is needed to access their pharmacy. Users discuss the cost-effectiveness of oral versus topical treatments, with some preferring oral minoxidil and finasteride due to fewer side effects.

PP405 is a potential hair loss treatment, but its safety and effectiveness are uncertain. Users advise caution and suggest waiting for more data before purchasing unverified versions.

Oral minoxidil is generally effective for hair loss but may cause side effects like heart palpitations and facial puffiness. Users highlight the importance of monitoring blood pressure due to potential cardiovascular risks.